JP5133708B2 - 非グリコシル化組換えコラーゲン様ポリペプチド - Google Patents
非グリコシル化組換えコラーゲン様ポリペプチド Download PDFInfo
- Publication number
- JP5133708B2 JP5133708B2 JP2007556099A JP2007556099A JP5133708B2 JP 5133708 B2 JP5133708 B2 JP 5133708B2 JP 2007556099 A JP2007556099 A JP 2007556099A JP 2007556099 A JP2007556099 A JP 2007556099A JP 5133708 B2 JP5133708 B2 JP 5133708B2
- Authority
- JP
- Japan
- Prior art keywords
- collagen
- polypeptide
- recombinant collagen
- glycosylated recombinant
- threonine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 108
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 103
- 229920001184 polypeptide Polymers 0.000 title claims description 100
- 239000004473 Threonine Substances 0.000 claims description 51
- 150000001413 amino acids Chemical class 0.000 claims description 51
- 235000001014 amino acid Nutrition 0.000 claims description 50
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 49
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 43
- 102000008186 Collagen Human genes 0.000 claims description 36
- 108010035532 Collagen Proteins 0.000 claims description 36
- 229920001436 collagen Polymers 0.000 claims description 36
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 32
- 235000004400 serine Nutrition 0.000 claims description 31
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 21
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 19
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 17
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 14
- 230000009477 glass transition Effects 0.000 claims description 14
- 244000005700 microbiome Species 0.000 claims description 10
- 241000235058 Komagataella pastoris Species 0.000 claims description 9
- 210000004899 c-terminal region Anatomy 0.000 claims description 9
- 229960005486 vaccine Drugs 0.000 claims description 9
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 8
- 241000235648 Pichia Species 0.000 claims description 8
- 235000004279 alanine Nutrition 0.000 claims description 8
- 239000004471 Glycine Substances 0.000 claims description 7
- 239000013543 active substance Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- 235000018417 cysteine Nutrition 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 241000320412 Ogataea angusta Species 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 241000206602 Eukaryota Species 0.000 claims 2
- 241000233866 Fungi Species 0.000 claims 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 description 49
- 235000008521 threonine Nutrition 0.000 description 47
- 108090000623 proteins and genes Proteins 0.000 description 25
- 108010010803 Gelatin Proteins 0.000 description 23
- 229920000159 gelatin Polymers 0.000 description 23
- 235000019322 gelatine Nutrition 0.000 description 23
- 235000011852 gelatine desserts Nutrition 0.000 description 23
- 230000013595 glycosylation Effects 0.000 description 23
- 238000006206 glycosylation reaction Methods 0.000 description 23
- 235000018102 proteins Nutrition 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 23
- 239000008273 gelatin Substances 0.000 description 22
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 14
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 11
- 230000026731 phosphorylation Effects 0.000 description 11
- 238000006366 phosphorylation reaction Methods 0.000 description 11
- 230000004989 O-glycosylation Effects 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 229960002591 hydroxyproline Drugs 0.000 description 9
- 235000000346 sugar Nutrition 0.000 description 9
- 210000004962 mammalian cell Anatomy 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 7
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 7
- 125000003275 alpha amino acid group Chemical group 0.000 description 7
- 230000029087 digestion Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 125000003607 serino group Chemical class [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 6
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
- 108090000631 Trypsin Proteins 0.000 description 5
- 102000004142 Trypsin Human genes 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 235000009582 asparagine Nutrition 0.000 description 5
- 229960001230 asparagine Drugs 0.000 description 5
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 150000007523 nucleic acids Chemical group 0.000 description 5
- 230000004481 post-translational protein modification Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 5
- 239000012588 trypsin Substances 0.000 description 5
- 230000004988 N-glycosylation Effects 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 101710137510 Saimiri transformation-associated protein Proteins 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 4
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 4
- 230000033444 hydroxylation Effects 0.000 description 4
- 238000005805 hydroxylation reaction Methods 0.000 description 4
- 238000001254 matrix assisted laser desorption--ionisation time-of-flight mass spectrum Methods 0.000 description 4
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 150000002482 oligosaccharides Chemical class 0.000 description 4
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 4
- 230000003252 repetitive effect Effects 0.000 description 4
- 150000003588 threonines Chemical class 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 3
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 3
- 235000011007 phosphoric acid Nutrition 0.000 description 3
- PCMORTLOPMLEFB-UHFFFAOYSA-N sinapinic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-UHFFFAOYSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 125000003508 trans-4-hydroxy-L-proline group Chemical group 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- BJBUEDPLEOHJGE-UHFFFAOYSA-N (2R,3S)-3-Hydroxy-2-pyrolidinecarboxylic acid Natural products OC1CCNC1C(O)=O BJBUEDPLEOHJGE-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 101001011741 Bos taurus Insulin Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101100274954 Homo sapiens COL1A1 gene Proteins 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002354 inductively-coupled plasma atomic emission spectroscopy Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- PCMORTLOPMLEFB-ONEGZZNKSA-N sinapic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- BJBUEDPLEOHJGE-IMJSIDKUSA-N trans-3-hydroxy-L-proline Chemical compound O[C@H]1CC[NH2+][C@@H]1C([O-])=O BJBUEDPLEOHJGE-IMJSIDKUSA-N 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- 102000008490 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Human genes 0.000 description 1
- 108010020504 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Proteins 0.000 description 1
- XGKCWNGHLZXLTK-MUWMCQJSSA-N 2-aminoacetic acid;(2s,3r)-2-amino-3-hydroxybutanoic acid Chemical compound NCC(O)=O.C[C@@H](O)[C@H](N)C(O)=O XGKCWNGHLZXLTK-MUWMCQJSSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 1
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000012511 carbohydrate analysis Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000001030 gas--liquid chromatography Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003262 industrial enzyme Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000006140 methanolysis reaction Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 150000002771 monosaccharide derivatives Chemical class 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 230000013777 protein digestion Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000006258 serine-glycosylation Effects 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000006227 trimethylsilylation reaction Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000004017 vitrification Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Description
本発明は、ヒトコラーゲンと比較して低い免疫効果及び酸性を有する、組換えによって生成したコラーゲン様ポリペプチドを対象とする。本発明は、コラーゲン様ポリマーが非グリコシル化状態であるように処置を講じることによって、これら両方の目的が達成されるという驚くべき考えに基づく。これらの処置は、以下の1つ又は複数を含む
−スレオニン、及び場合によってはセリンと他のアミノ酸の置換、
−スレオニン、及び場合によってはセリンが存在しないポリペプチド配列の選択又は
−各スレオニンのN末端側近辺へのグリシンの配置、及び/又は各スレオニンのC末端側近辺へのプロリンの配置、及び場合によってはセリンの少なくとも50%のC末端側近辺へのプロリンの配置;例えば点突然変異により前記残基に隣接するアミノ酸を置換することによって、これを実施することができる。
エアロゾル又は粘着物質も使用されることが知られている。全てのこのような化粧品調製物は、非グリコシル化ポリペプチドを含むことができる。本発明の非グリコシル化ポリペプチドの施用は、油又はアルコールの使用を不要にし、このような物質に対する免疫反応、又は皮膚の低下した防御機能のような望ましくない影響を妨げるのにさらに助力する。
[実施例]
スレオニン又はセリンを含まない本発明のコラーゲン様ポリペプチド(CLP−1)を、ヒトCOL1A1−1のゼラチンのアミノ酸配列(配列番号1)の一部分をコードする核酸配列で始めることによって生成した。EP−A−0926543、EP−A−1014176及びWO01/34646中に開示されたのと同様の方法を使用した。本発明によるこのコラーゲン様ポリペプチドCLP−1の配列は以下に与える(配列番号2)。
GPPGPAGQDGRPGPPGPPGARGQAGVMGFPGPKGAAGEPGKAGERGVPGPPGAVGP
AGKDGEAGAQGPPGPAGPAGERGEQGPAG(配列番号1のアミノ酸554〜638)
スレオニンとセリンの両方を含む比較可能なコラーゲン様ポリペプチド(CLP−2)は、ヒトCOL1A1−1のゼラチンのアミノ酸配列の一部分をコードする核酸配列で始めることによって生成した。EP−A−0926543、EP−A−1014176及びWO01/34646中に開示されたのと同様の方法を使用した。本発明によるこのゼラチンの配列は以下に与える(配列番号3)。EP1398324A中に記載されたのと同様に、CLP−2はCOL1A1から選択した配列の3量体である。
MALDI−TOF(マトリックス支援レーザー脱離イオン化質量分析法)による詳細な質量分光分析を、CLP−2(配列番号3;スレオニンとセリンの両方を含む)に行った。完全タンパク質以外に、トリプシンによる消化産物、V8プロテアーゼ(glu−C)による消化産物及びアルカリホスファターゼによる消化産物も分析した。
タンパク質の消化
凍結乾燥CLP−2を20mg/mlの濃度で脱イオン水に溶かし、次いで後に消化バッファーに10倍希釈した。消化バッファーは、glu−C(V8)消化用には50mMのリン酸ナトリウム、pH7.8、及びトリプシン消化用には100mMの重炭酸アンモニウム、pH7.8であった。消化バッファーに溶かした2mg/mlのタンパク質溶液0.5mlを20μlの酵素溶液(両方の場合1mg/ml)と混合させて、1:50w/wの基質:酵素比を得た。インキュベーションは一晩37℃で進行させた。glu−C消化タンパク質の等分試料を、比1:50w/wでトリプシンと共に一晩再度インキュベートして、2回消化されたサンプルを得た。
10mg/mlの濃度で50mMの炭酸バッファー(pH9.5)中にCLP−2を溶かした。1μlのアルカリホスファターゼ溶液(Sigma社製、P−6774、20DEA単位/μl)を、500μlのタンパク質溶液に加えた。混合物は2時間37℃でインキュベートした。反応したタンパク質の等分試料を50mMの重炭酸バッファー、pH8.1と1:3(V/V)で混合させ、比1:50w/wでトリプシンと共に一晩再度インキュベートして、消化されたサンプルを得た。
前に記載した全てのCLP−2消化産物は、以下のようにMALDI分析用に調製した:10μlの消化産物をジップチップC18(Millipore社製)によって精製/脱塩し、3μlのアセトニトリル/0.1%TFA1:1(V/V)に溶出させた。リニアモード分析用に、1μlの等分試料をシナピン酸マトリックス(飽和3,5−ジメトキシ−4−ヒドロキシ桂皮酸、アセトニトリル中/0.1%TFA1:2(V/V))と1:2で混合させ、一方リフレクトロンモード分析用に、他の1μlの等分試料をDHBマトリックス(20mg/mlの2,5ジヒドロキシ安息香酸、アセトニトリル中/0.1%TFA1:1(V/V))と1:2で混合させた。この調製の唯一の例外は、リフレクトロンモードに関するCLP−2のトリプシンによる消化産物であった。この場合、消化産物をマトリックスDHBと直接1:5で混合させ、MALDI標的にスポットした。
MALDI−TOF MSスペクトルを、Bruker Biflex III質量分析器においてリフレクトロンモード又はリニアモードのいずれかで得た。リニアモードは完全タンパク質又は2000Daより大きなタンパク質断片の分析用に使用し、一方リフレクトロンモードはm/z範囲500〜3000でペプチドマップに使用した。
炭水化物の分析を行って、GC−MSによってCLP−2のグリコシル化の性質を確認した。
分析はCLP−2中の750〜1000mg/kgのリン光体含量を示す。わずか約70mg/kgの合計リン光体含量がリン酸に由来する(データ示さず)。残りの部分はおそらくリン酸化由来のものである。
CLP−2の質量は理論質量より有意に大きい(表1参照)。CLP−2のトリプシンによる消化は、2つのピーク及び予想質量と一致しない質量を示す。これらのピークは、幾つかのサテライトピーク及び80の質量差を示す。これは多数のリン酸化(9個までのリン酸)に原因がある可能性がある。これをICP−OESによって確認した。
Claims (19)
- Gly−Xaa−Yaaトリプレットが5回以上連続して反復するひと続きの配列を少なくとも含み、アミノ酸の少なくとも20%が連続Gly−Xaa−Yaaトリプレットの形で存在する非グリコシル化組換えコラーゲン様ポリペプチドであって、
前記コラーゲン様ポリペプチド中、スレオニンが存在しないか、又はグリシンが各スレオニンのN末端側に隣接して存在し、及び/若しくはプロリンが各スレオニンのC末端側に隣接して存在し、
且つ前記組換えコラーゲン様ポリペプチドが微生物中で発現されることを特徴とする、非グリコシル化組換えコラーゲン様ポリペプチド。 - 天然コラーゲン中に存在するアミノ酸配列と少なくとも80パーセント同一であるアミノ酸配列を有する、請求項1に記載の非グリコシル化組換えコラーゲン様ポリペプチド。
- スレオニンが存在しないか、或いは全スレオニンがセリン又はアラニン又はシステインによって置換されている、請求項1又は2に記載の非グリコシル化組換えコラーゲン様ポリペプチド。
- セリンの少なくとも50パーセントがプロリンと隣接しており、前記プロリンがセリンのC末端側に位置するか、又はセリンが存在しない、請求項1〜3のいずれかに記載の非グリコシル化組換えコラーゲン様ポリペプチド。
- 微生物が真核生物である、請求項1〜4のいずれかに記載の非グリコシル化組換えコラーゲン様ポリペプチド。
- 真核生物が真菌である、請求項5に記載の非グリコシル化組換えコラーゲン様ポリペプチド。
- 真菌が酵母である、請求項6に記載の非グリコシル化組換えコラーゲン様ポリペプチド。
- 酵母がメチロトローフ酵母である、請求項7に記載の非グリコシル化組換えコラーゲン様ポリペプチド。
- メチロトローフ酵母がピキア又はハンセヌラ種である、請求項8に記載の非グリコシル化組換えコラーゲン様ポリペプチド。
- メチロトローフ酵母が、ピキア・パストリス又はハンセヌラ・ポリモルファである、請求項9に記載の非グリコシル化組換えコラーゲン様ポリペプチド。
- プロリン及びリシンがヒドロキシル化されていない、請求項1〜10のいずれかに記載の非グリコシル化組換えコラーゲン様ポリペプチド。
- コラーゲン様ポリペプチドが8未満の等電点を有する、請求項1〜11のいずれかに記載の非グリコシル化組換えコラーゲン様ポリペプチド。
- 30キロダルトン未満であり、1.5キロダルトンを超える分子量を有する、請求項1〜12のいずれかに記載の非グリコシル化組換えコラーゲン様ポリペプチド。
- 10キロダルトン未満であり、3キロダルトンを超える分子量を有する、請求項1〜13のいずれかに記載の非グリコシル化組換えコラーゲン様ポリペプチド。
- 少なくとも180℃の推定ガラス転移温度を有する、請求項13又は14に記載の非グリコシル化組換えコラーゲン様ポリペプチド。
- 生理学的活性物質、及び請求項13〜15のいずれかに記載の非グリコシル化組換えコラーゲン様ポリペプチドを含む医薬組成物。
- 薬学的に許容される担体をさらに含む、請求項16に記載の医薬組成物。
- ワクチンである、請求項16又は17に記載の医薬組成物。
- 請求項1〜15のいずれかに記載の非グリコシル化組換えコラーゲン様ポリペプチドを含む凍結乾燥組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05075439.9 | 2005-02-23 | ||
EP05075439 | 2005-02-23 | ||
PCT/NL2006/050030 WO2006091099A2 (en) | 2005-02-23 | 2006-02-22 | Non-glycosylated recombinant collagen-like polypeptides |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008537929A JP2008537929A (ja) | 2008-10-02 |
JP5133708B2 true JP5133708B2 (ja) | 2013-01-30 |
Family
ID=34938067
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007556099A Active JP5133708B2 (ja) | 2005-02-23 | 2006-02-22 | 非グリコシル化組換えコラーゲン様ポリペプチド |
Country Status (5)
Country | Link |
---|---|
US (1) | US7932353B2 (ja) |
EP (1) | EP1856152B1 (ja) |
JP (1) | JP5133708B2 (ja) |
DE (1) | DE602006015289D1 (ja) |
WO (1) | WO2006091099A2 (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1961411A1 (en) * | 2007-02-21 | 2008-08-27 | FUJIFILM Manufacturing Europe B.V. | A controlled release composition |
EP1961414A1 (en) * | 2007-02-21 | 2008-08-27 | FUJIFILM Manufacturing Europe B.V. | A controlled release composition comprising a recombinant gelatin |
ATE554103T1 (de) * | 2007-02-21 | 2012-05-15 | Fujifilm Mfg Europe Bv | Rgd-haltige rekombinante gelatine |
WO2010143708A1 (ja) * | 2009-06-12 | 2010-12-16 | 富士フイルム株式会社 | 新生血管に対する標的化剤 |
EP2648812A2 (en) * | 2010-12-07 | 2013-10-16 | The Trustees of Columbia University in the City of New York | Network material devices, methods, and systems |
JP5992529B2 (ja) * | 2012-09-26 | 2016-09-14 | 富士フイルム株式会社 | ポリペプチド、足場組成物、軟骨組織修復用組成物、軟骨細胞培養用組成物及びグリコサミノグリカン産生促進用組成物 |
US11180541B2 (en) | 2017-09-28 | 2021-11-23 | Geltor, Inc. | Recombinant collagen and elastin molecules and uses thereof |
US11168126B2 (en) | 2019-04-12 | 2021-11-09 | Geltor, Inc. | Recombinant elastin and production thereof |
CN115298212A (zh) | 2020-01-24 | 2022-11-04 | 格尔托公司 | 无动物膳食胶原蛋白 |
CN112552393B (zh) * | 2020-12-31 | 2022-02-01 | 西安德诺海思医疗科技有限公司 | 一种重组人源iii型胶原蛋白及其毕赤酵母重组表达系统 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH629709A5 (de) | 1979-01-09 | 1982-05-14 | Francesco Sbarro | Elektrowagen. |
DE3644210C2 (de) | 1986-12-23 | 1994-01-27 | Werner Doppstadt | Gerät zum Zerkleinern von organischem Abfall |
US20030064436A1 (en) | 1996-10-29 | 2003-04-03 | Vaughan Paul Richard | Method for producing, in yeast, a hydroxylated triple helical protein, and yeast host cells useful in said method |
NL1007908C2 (nl) * | 1997-12-24 | 1999-06-25 | Fuji Photo Film Bv | Zilverhalide-emulsies met recombinant collageen die geschikt zijn voor fotografische toediening alsmede de bereiding daarvan. |
KR20020059719A (ko) | 1999-11-12 | 2002-07-13 | 추후보정 | 재조합 젤라틴 |
EP1398324A1 (en) | 2002-09-11 | 2004-03-17 | Fuji Photo Film B.V. | Use of recombinant gelatin-like proteins as plasma expanders and compositions suitable for plasma substitution |
WO2004075871A1 (en) | 2003-02-26 | 2004-09-10 | Fuji Photo Film B.V. | Cosmetic uv-screen compositions and aminobutadiene-based uv-absorbing complexes therefor |
-
2006
- 2006-02-22 WO PCT/NL2006/050030 patent/WO2006091099A2/en active Application Filing
- 2006-02-22 JP JP2007556099A patent/JP5133708B2/ja active Active
- 2006-02-22 DE DE602006015289T patent/DE602006015289D1/de active Active
- 2006-02-22 EP EP06716664A patent/EP1856152B1/en active Active
- 2006-02-22 US US11/817,006 patent/US7932353B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2008537929A (ja) | 2008-10-02 |
US7932353B2 (en) | 2011-04-26 |
US20080107666A1 (en) | 2008-05-08 |
WO2006091099A2 (en) | 2006-08-31 |
EP1856152A2 (en) | 2007-11-21 |
DE602006015289D1 (de) | 2010-08-19 |
WO2006091099A3 (en) | 2006-11-23 |
EP1856152B1 (en) | 2010-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5133708B2 (ja) | 非グリコシル化組換えコラーゲン様ポリペプチド | |
Cardamone | Investigating the microstructure of keratin extracted from wool: Peptide sequence (MALDI-TOF/TOF) and protein conformation (FTIR) | |
Muller et al. | Localization of O-glycosylation sites on glycopeptide fragments from lactation-associated MUC1 | |
Muller et al. | High density O-glycosylation on tandem repeat peptide from secretory MUC1 of T47D breast cancer cells | |
Yang et al. | Surfactant protein B propeptide contains a saposin-like protein domain with antimicrobial activity at low pH | |
Weyer et al. | Cytochrome subunit of the photosynthetic reaction center from Rhodopseudomonas viridis is a lipoprotein | |
JP4423542B2 (ja) | 抗菌性ポリペプチド及びその利用 | |
Jensen et al. | Characterization of the oligomer structure of recombinant human mannan-binding lectin | |
JP2018527288A (ja) | 極性の組換え延長部を有するインスリン | |
Park et al. | Enhancement of recombinant human EPO production and glycosylation in serum-free suspension culture of CHO cells through expression and supplementation of 30Kc19 | |
TR201815592T4 (tr) | Serum amiloid p türevleri ve bunların preparasyonu ve kullanımı. | |
SA516371859B1 (ar) | سلفاميداز معدل وإنتاجه | |
Stoeva et al. | Primary structure and unusual carbohydrate moiety of functional unit 2-c of keyhole limpet hemocyanin (KLH) | |
US20070031501A1 (en) | Use of recombinant or synthetic gelatin-like proteins as stabiliser in lyophilized pharmaceutical compositions | |
US20070287826A1 (en) | Production of high molecular mass lectins | |
de Groot et al. | Deglycosylation of ovalbumin prohibits formation of a heat‐stable conformer | |
Giuffrida et al. | The Unusual Amino Acid Triplet Asn–Ile–Cys Is a Glycosylation Consensus Site in Human α-Lactalbumin | |
Arcone et al. | Structural characterization of a biologically active human lipocortin 1 expressed in Escherichia coli | |
CA2237543A1 (en) | New form of amphiregulin, methods for producing and using the same and compositions comprising the same | |
Stoeva et al. | Primary structure, isoforms, and molecular modeling of a chitin-binding mistletoe lectin | |
Dolashka-Angelova et al. | A challenging insight on the structural unit 1 of molluscan Rapana venosa hemocyanin | |
Lyimo et al. | Primary structure and specificity of a new member of galectin family from the Amethyst deceiver mushroom Laccaria amethystina | |
WO2011122127A1 (ja) | 骨芽細胞増殖促進活性を有するペプチドおよびその利用 | |
JP2009203223A (ja) | 凍結乾燥用保護剤及び生理活性物質の製造方法 | |
HUT73320A (en) | A method of detecting the presence of and converting of a polypeptide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080730 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090121 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110719 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111012 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120702 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120920 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20121016 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121108 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151116 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5133708 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |